Publications by authors named "Yoshinori Munetomo"
Not all patients with ulcerative colitis (UC) respond initially to treatment with biologic agents, and predicting their efficacy prior to treatment is difficult. Vedolizumab, a humanized monoclonal antibody against alpha 4 beta 7 (α4β7) integrin, suppresses immune cell migration by blocking the interaction between α4β7 integrin and mucosal addressin cell adhesion molecule 1. Reports about histological features that predict vedolizumab efficacy are scarce.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated the impact of immunomodulators (IMs) on relapse rates in ulcerative colitis (UC) patients who stopped anti-TNF-α antibody treatment.
- 257 patients were followed over a median of 22 months, with 114 experiencing relapses, but IMs did not significantly affect relapse rates compared to those who did not take IMs.
- Factors like discontinuations due to side effects and younger age were found to predict higher relapse risks, suggesting the need for careful monitoring in these cases.
Objective: This study aimed to assess the efficacy and tolerability of leukocytapheresis (LCAP) and to investigate predictive factors for mucosal healing and a sustained clinical response in steroid-free and steroid-refractory patients with ulcerative colitis (UC).
Material And Methods: Thirty-one steroid-free or steroid-refractory patients with active UC were enrolled. Five or ten consecutive sessions of LCAP were performed in each patient.